The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases.
Am J Reprod Immunol
; 75(6): 654-60, 2016 06.
Article
en En
| MEDLINE
| ID: mdl-27145741
ABSTRACT
PROBLEM:
Cyclosporin A (CYS A) is an immunosuppressant agent administered in autoimmune diseases, and its use during pregnancy and lactation is a debated topic. METHOD OF STUDY The demographic characteristics, the activity of the underlying disease, and the onset of fetal-maternal complications have been investigated in 21 consecutive patients (2 RA, 14 SLE, 2 PA, 1 SjS, 1 DM, 1 Churg-Strauss vasculitis), treated with CYS A throughout 29 gestations. A subanalysis of the SLE group was performed.RESULTS:
We recorded a live birth rate of 86.2%. The median gestational age at birth was 38.2 weeks. The prevalence of maternal-fetal complications showed no differences with general population. Disease flares appeared in 4% of patients during gestation and in 12% during puerperium.CONCLUSION:
We found no evidence justifying the suspension of CYS A when a pregnancy occurs. The drug does not appear to promote maternal-fetal complications and should be continued in patients who benefit from therapy. Data regarding breast-feeding during therapy are still scarce, but no evidence of toxicity has emerged.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Complicaciones del Embarazo
/
Enfermedades Autoinmunes
/
Ciclosporina
/
Inmunosupresores
Tipo de estudio:
Prevalence_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Pregnancy
País/Región como asunto:
Europa
Idioma:
En
Revista:
Am J Reprod Immunol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Italia